Galapagos NV (GLPG)
After hours:
| Previous Close | 54.24 |
| Open | 55.51 |
| Bid | 56.50 x 800 |
| Ask | 55.77 x 900 |
| Day's Range | 54.88 - 56.00 |
| 52 Week Range | 46.41 - 72.11 |
| Volume | |
| Avg. Volume | 315,637 |
| Market Cap | 3.661B |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 74.51 |
- GlobeNewswire
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in partnership with Lonza, and AboundBio’s cutting-edge fully human antibody-based capabilities, providing a platform of next-generation CAR-Ts and bispecific antibodiesClinical validation of decentralized production platform with CD19 CAR-T in 2 Phase 1/2a studies in relapsed/refractory Non-Hodgkin’s-Lymphoma (rrNHL) and Chronic Lymphocytic Leukemia (rrCLL) ongoing, with topline resul
- GlobeNewswire
Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 80,290 new ordinary shares on 20 June 2022, for a total capital increase (including issuance premium) of EUR 1,459,506.60. Pursuant to the subscription right exercise program for Galapagos’ executive committee, the members of the executive committee automatically are committed to exercise a minimu
- Zacks
Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?
The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
